SequelSEC

Jasper Therapeutics, Inc. JSPR

Biological Products, (No Diagnostic Substances) · CIK 0001788028 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$83.88M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Jasper Therapeutics, Inc. (JSPR) reported net income of -$75.80M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Jasper Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Jasper Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenue$41.64M$34.27MUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$83.88M-$76.24M-$68.86M-$51.20M-$36.83M-$20.68M
Net income-$75.80M-$71.27M-$64.46M-$37.68M-$30.64M-$31.67M
Research & development$63.10M$55.82M$51.78M$34.63M$25.42M$15.88M
Weighted-average diluted sharesshares 19.17Mshares 14.58Mshares 10.44Mshares 3.65Mshares 11.39MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailable-$6.44M
Income tax expenseUnavailable$2.00K$2.00KUnavailableUnavailable$38.45K
Diluted EPS$-3.95$-4.89$-6.18$-10.33$-2.69Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$20.78M$20.42M$17.08M$16.57M$11.41M$4.80M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Jasper Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$28.69M$71.64M$86.89M$38.25M$84.70M$19.84M
Total assets$35.78M$79.90M$94.89M$48.36M$93.65M$23.36M
Current assets$34.64M$75.81M$88.94M$41.73M$87.83M$20.68M
Total liabilities$31.63M$18.22M$16.45M$12.37M$24.14M$14.65M
Current liabilities$13.20M$15.24M$12.37M$7.06M$8.02M$4.01M
Total equity incl. NCI$4.15M$61.67M$78.44M$35.99M$69.52M-$35.13M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable$43.84M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$6.22M$4.03M$4.15M$1.77M$3.92M$1.42M

Cash flow

Jasper Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$77.16M-$62.60M-$52.07M-$45.86M-$33.68M-$18.27M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow$5.00K-$532.00K-$267.00K-$576.00K-$2.43M$198.34K
Financing cash flow$34.21M$47.88M$100.97M$55.00K$100.97M$11.29M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailable-$442.64K
Stock-based compensation$6.71M$6.62M$5.21M$4.09M$1.05M$1.21M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$1.06M$1.37M$1.11M$975.00K$377.00KUnavailable

Derived

Jasper Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio2.62x4.98x7.19x5.91x10.95x5.16x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open JSPR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

cash flow reconciliationreview2020-12-31

Operating, investing and financing flows differ from the reported change in cash by 6339016, beyond tolerance 1000000.